New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
08:39 EDTCMRXChimerix shares remain undervalued, says Cowen
Cowen believes shares of Chimerix remain undervalued following its dinner management. The firm remains confident its SUPPRESS trial for brincidofovir will succeed in 2015 and expects other opportunities for the drug to materialize in 2014. Shares are Outperform rated with a $27 price target.
News For CMRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
10:01 EDTCMRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:37 EDTCMRXChimerix initiated with an Overweight at Barclays
Target $55.
March 2, 2015
06:28 EDTCMRXFujifilm CEO says 'ready' for large orders of Avigan drug for Ebola, WSJ reports
Fujifilm’s (FUJIY) Avigan drug, which has shown signs of efficacy against the Ebola virus, has drawn interest from about 20 countries, The Wall Street Journal reports, citing comments made by CEO Shigetaka Komori. The drug was developed by Toyama Chemical, a Fujifilm unit, and Komori said the company is ready for large orders. Other drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
February 26, 2015
07:40 EDTCMRXChimerix provides update on SUPPRESS trial enrollment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use